Trevi Therapeutics, Inc. (TRVI) Stock

Trevi Therapeutics, Inc. (TRVI) is a Healthcare stock trading at $17.20 (as of 2026-06-18), with a market capitalization of $2.01B and a trailing P/E of -44.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine. It is developing Haduvio for conditions including chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis, and it holds a license agreement with Endo Pharmaceuticals to develop and commercialize products using nalbuphine hydrochloride.

Valuation — source: SEC EDGAR (first-party)
Price	$17.20
Market Cap	$2.01B
P/E Ratio	-44.2
EV / EBITDA	-37.8
Price / Book	11.66
DCF Value (model)	$-5.43
DCF Upside vs Price	-131.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.54M
Net Margin	-654.2%
Return on Equity	-26.5%
Current Ratio	24.75
Revenue Growth (YoY)	50.8%
EPS Growth (YoY)	0.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	127.91 (safe)

Valuation vs Sector & Industry
Stock P/E	-44.2
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-310.8%
vs Industry	-356.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	NEA Management Company, LLC ($157.74M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jennifer L. Good
Employees	31
Country	US
IPO Date	2019-05-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.